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INTRODUCTION 
Pseudomonas aeruginosa is a major opportunistic pathogen. 
I t  causes severe infections in a wide spectrum of clinical 
settings, including nosocomial pneumonia, septicemia 
in neutropenic cancer patients and burns patients, 
chronic destructive lung infection in cystic fibrosis 
patients, and severe infections in patients with AIDS. 
High mortality and morbidity have been observed in 
l? aeruginosa infections. This is due to the capacity of 
l? aeruginosa to adapt easily to changes in its environ- 
ment, to rapidly become resistant to antibiotics, and to 
produce a variety of virulence factors. 
l? aeruginosa represents a paradigm of antibiotic 
resistance, since practically all known mechanisins of 
bacterial resistance can be seen in this species. 
PATTERNS OF RESISTANCE TO P-LACTAMS IN 
F? AERUGINOSA 
Natural resistance 
l? aeruginosa is naturally resistant to many antibiotics. 
This is due to a relatively impermeable outer mem- 
brane (about 1/100 of the permeability determined in 
Eschericlzia coli [l]) and to constitutively expressed efflux 
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systems. In addition, the naturally occurring AmpC 
p-lactamase, even when expressed at basal levels, 
confers resistance to penicillin G, aminopenicillins, and 
most of the early cephalosporins. This (3-lactamase is 
not inhibited by the available P-lactamase inhibitors 
and therefore confers resistance to antibiotic combina- 
tions comprising an aminopenicillin with clavulanic 
acid, sulbactam and tazobactam [Z]. The MICso of 
drugs like ceftriaxone or cefotaxime is 2 8  mg/L [3],  
meaning that they have no clinical use for pseudomonal 
infections. Only carboxypenicillins like ticarcillin, 
acylureidopenicillins like piperacillin, acylpenicillins 
like apacillin, certain cephalosporins such as cefsulodin, 
ceftazidime, cefepime or cefpirome, monobactams 
(aztreonam) and carbapenems (imipenem, meropenem) 
are sufficiently active for therapeutic use in susceptible 
l? aeruginosa infections. 
Acquired resistance 
l? aeruginosa can easily acquire mechanisms of resistance, 
creating frequent therapeutic problems. At least five 
different p-lactam patterns are observed. 
The susceptible phenotype includes susceptibility 
to ticarcillin, piperacillin, cefsulodin, ceftazidime, 
aztreonam, imipenem and meropenem [3]. A first 
resistant phenotype, often called ‘intrinsic resistance 
to carbenicillin’ [4] (even though it affects many other 
drugs) is characterized by MIC increases of 4-%fold 
for most p-lactams, including meropenem but not 
imipenem, and the absence of P-lactamase production 
above basal levels. This phenotype includes increased 
resistance to non-p-lactam antibiotics like quinolones, 
trimethoprim, tetracycline and chloramphenicol. 
Initially it was thought to be caused by decreased outer- 
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membrane permeability, but recent observations have 
attributed most of this phenomenon to activation or 
derepression of active efflux systems [4]. Derepression 
of the AmpC chromosomal p-lactamase produces a 
second resistance phenotype, where all p-lactams, except 
some recent cephalosporins (cefepime, cefpirome) and 
carbapenems, are affected to different degrees, depend- 
ing on the level of 0-lactam production. The presence 
of an OXA-type (oxacillinase) p-lactamase generates a 
pattern where penicillins, in particular ticarcillin, 
azlocillin and piperacillin, appear to be more affected 
than cephalosporins 131. A fourth phenotype is charac- 
terized by increased MICs limited to carbapenems, 
when other p-lactams are not affected. This pattern 
corresponds to decreased outer-membrane expression 
of the specific porin OprD. A variety of other pheno- 
types are generated by the production of secondary, 
extended-spectrum p-lactamases mediated by mobile 
genetic elements, as discussed below. O n  practical 
grounds, several mechanisms of resistance can coexist 
in the same clinical strain, making difficult the recog- 
nition of a given mechanism from the susceptibility 
pattern. I! aeruginosa resistant to all p-lactams can be 
observed. 
MECHANISMS OF 0-LACTAM RESISTANCE IN 
k? AERUGINOSA 
AU mechanisms known to produce bacterial resistance 
to p-lactams can be found in I? aeruginosa: production 
of p-lactamase, altered permeability, active efflux, and 
changes in the target molecule. 
Resistance by P-lactamase production 
Enzymatic production represents the main mechanism 
of acquired resistance in I! aeruginosa, as in other Gram- 
negative rods. More than 20 different enzymes have 
been described so far in this species [5]. 
The class C chromosomal enzyme is responsible for 
most of the cases of p-lactam resistance occurring 
during therapy with p-lactams [6,7]. It is encoded by 
the ampC gene linked to the regulatory ampR (repressor) 
gene. The 0-lactamase production is generally in- 
ducible, in particular by imipenem, but selection of 
derepressed mutants seems to account for most of the 
resistance. The sensitive inducible population is supposed 
to be overrun by the pre-existing resistant derepressed 
subpopulation as a consequence of the 0-lactam pressure 
[8]. However, the genetic events leading to chromo- 
somal 0-lactamase overproduction in I? aeruginosa isolates 
from patients have not been formally elucidated. AmpC 
derepression is still a hypothesis. In particular, the 
ampC-ampR region appears to be unchanged in some 
of the P-lactamase overproducers sampled fiom patients, 
and the enhanced p-lactamase expression could be 
caused by mutations in regulatory proteins other than 
The acquisition of secondary p-lactamases encoded 
by mobile genetic elements (plasmid, transposon, 
integron) seems to be host specific. I! aeruginosa can 
acquire class A, B and D p-lactamases, but most of the 
classic TEM and SHV types commonly encountered in 
Enterobacteriaceae are not seen in this species (Table 
1). Class A enzymes from I? aeruginosa include the four 
broad-spectrum penicillinases indicated in Table 1, 
which show high homology [5]. In addition, three 
extended-spectrum, plasmid-mediated enzymes confer 
additional resistance to ureidopenicillins, ceftazidime, 
cefepime and cefpirome, but are inhibited by clavulanic 
acid and tazobactam [2]. Class B enzymes are repre- 
sented in I! aeruginosa by IMP-1, which hydrolyzes 
most p-lactams, including all cephalosporins, imipenem 
and meropenem [9]. Aztreonam and piperacillin are 
less affected, but IMP-1 activity is not inhibited by 
clavulanic acid or tazobactam [2]. IMP-1 seems to be 
limited to Japan so far, where it has generated 
frightening multifocal outbreaks [lo]. Class D enzymes 
include the large group of oxacillinases which seem to 
derive from the same ancestor. Most of them can be 
missed, in the routine laboratory in particular, because 
they are not effectively inhibited by clavulanic acid. 
OXA-18 is distinctive since it has low amino acid 
homology with the other enzymes in its class [ll], it 
hydrolyzes ceftazidime and aztreonam (similar to class 
AmPR [61. 
Table 1 p Lactamases identified in I? aeruginosa [2,5] 
Class of enzyme Main characteristics Enzymes 
Class C Chromosomal cephalosporinase AmpC 
Class A Broad-spectrum penicillinases PSE-1, PSE-4, CAR€-3, CARB-4 
Extended-spectrum enzymes TEM-42, SHV-2a, PER-I 
Class B Carbapenemases or metalloenzymes IMP-1 
Class D OxaciUinases Om-2, Om-3, Om-5, OXA-7, O m - 1 0 ,  OXA-13, Om-20 
Broad-spectrum oxacillinases OXA-11, Om-14, O m - 1 5 ,  Om-16, OXA-18, O m - 1 9  
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A enzymes [2] ) ,  and it is inhibited by clavulanic acid. 
Some of the other.OXA-type enzymes also display an 
extended spectrum of activity, affecting, in particular, 
ceftazidinie. In this case, cefepime may still be active 
(e.g. OXA-10, OXA-15, OXA-18) or inefficient 
(OXA-11 or OXA-14) [5]. 
Resistance by altered outer-membrane permeability 
The majority of imipenem-resistant l? aeruginosa clinical 
isolates exhibit a porin OprD deficiency [12-14]. OprD 
is a specific channel promoting the entry ofbasic amino 
acids and carbapenems [13]. Meropenem appears to be 
slightly less affected than imipenem in OprD-deficient 
isolates. OprD deficiency produces resistance only when 
chromosonial p-lactamase is expressed, exemplifying 
the interplay between the two resistance mechanisms 
[IS]. Actually, among other factors such as the affinity 
for target molecules and efflux, the MIC of a strain 
depends upon a balance between the number of imi- 
penem molecules entering into the periplasmic space 
and the number of those that are inhibited by the 
p-lactamase as shown in the Enterobacter cloacae model 
P61. 
Resistance by active efflux 
Until recently, it was believed that permeability mutants 
could also contribute to resistance to non-carbapenem 
antipseudomonal p-lactam antibiotics. Recent investi- 
gations seem to rule out this possibility [17], since the 
activity of these p-lactams were not affected in a 
collection of porin-deficient mutants. In 1993 it 
became clear that the overexpressed outer-membrane 
proteins, often observed in P-lactam-resistant isolates, 
did not affect permeability but were actually part of 
niultidrug efflux systems with broad substrate specificity. 
Active efflux is a recently described mechanism of 
resistance to p-lactanis in I? aertrginosa, where at least 
four geneticdly distinct systems seem to coexist. To 
limit the description to the three well-described 
systems, each of them is composed of three proteins. 
A cytoplasmic membrane protein (MexB, MexD or 
Mex F) is thought to act as an energy-dependent pump 
with broad substrate specificity. A second protein 
(OprM, OprJ or OprN) is located in the outer 
membrane. A third protein (MexA, MexC or MexE) 
is located in the periplasmic space and thought to make 
a link between the two other proteins. The con- 
stitutively expressed MexA-MexB-OprM efflux 
system [18], when derepressed, produces the previously 
described nalB- type mutants, conferring resistance 
to most p-lactams (penicillins, cephalosporins, mono- 
bactams) with the exception of imipenem (Table 2), 
although meropenem is a substrate [20]. The MexC- 
MexD-OprJ efflux system, corresponding to the n@B- 
type mutants [21], confers resistance to zwitterionic 
cephems like cefepime and cefpirome. Increased 
susceptibility is documented with other p-lactams. This 
surprising observation is due to the fact that over- 
expression of MexC-MexD-OprJ is accompanied by 
decreased expression of MexA-MexB-OprM [22]. 
The third multidrug efflux system, called Me&- 
MexF-OprN, is overexpressed in nzxC-type mutants 
[23]. I t  does not seem to extrude p-lactams, but is 
regularly associated with decreased expression of OprD, 
leading to resistance to carbapenems. 
Resistance by altered target 
Modified penicillin-binding proteins (PBPs) seem to be 
more rarely associated with emergence of resistance 
during p-lactam therapy, but altered PBP-4 has been 
reported after treatment with imipenem [24]; after high 
doses of piperacillin in a cystic fibrosis patient, the 
graduated decrease in PBP affinity for ['4C]penicillin G 
was correlated with increasing p-lactani resistance and 
increasing PBP-6 expression 1251. Recently, it was 
shown that l? aevtrginosa overproducing PSP-3 displayed 
reduced susceptibility to p-lactanis [26]. 
CONCLUSIONS 
To a variety of synthetic antipseudomonal antibiotics, 
I? aertrginosa demonstrates a variety of resistance mech- 
Table 2 Active enlux systems in I! aenqinosa and activities of p lactam antibiotics 
Etflux system B Lactanis affected when this system is activated (fold variation in MICs)" 
~~ ~~~ 
MexA-Me&-OprM Carbenicillin (x8) ,  ticarcillin (ND), piperacillin (NL)), aztreonam (X 16), ceftazidime (X 8), cefeplme (X 4), 
cefpirome ( x 4), nieropeneni ( x 4) 
Cefepime ( X  8) ,  cefpirome (X 8) ,  
carbenicillin (XO.25), aztreonam (xO.50), meropmem (X0.5)b 
Innpenem (X 8) ,  meropenem ( X  4) (by decrease of OprD expression) 
MexC-MexD-OprJ 
Me&-MexF-OprN 
'As measured in genetically defined mutants. 
hIn some strains, increased susceptibility (maximum: X 0.12) is observed. 
ND, not determined. 
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anisms. Strains displaying resistance to all p-lactams 
exist but, fortunately, represent only a minority of 
clinical isolates so far. Most authorities feel that p- 
lactams are still our best weapon for treating severe I? 
aeruginosa infections, and the clinician must know how 
to select the most appropriate molecule. Two different 
situations may be distinguished: the so-called empirical 
therapy, i.e. without microbiological confirmation, and 
the therapy of infection, where the pathogen is fully 
identified and tested. If, in the latter case, selection of 
a p-lactam depends on the usual considerations 
(susceptibility, route of administration, cost, local 
preference), the former can be difficult. When a p- 
lactam is chosen, it is important to consider the local 
epidemiology in this selection. There is a debate 
regarding the possibility of using a ‘cycling’ policy, i.e. 
using different compounds for the same indication in 
the same institution at a given time, in order to 
multiply the attack points on the bacterium. Epidemio- 
logic data with which to judge such an approach are 
still missing, but the microbiological rationale exists. In 
its capacity to produce human infections, I? aeruginosa 
is essentially a nosocomial pathogen, meaning that 
hospital strains may successively infect several patients, 
being exposed to a series of antibiotic treatments. From 
the bacterial side it is probably more dif‘iicult to handle 
multidirectional attacks, obliging it to develop multiple 
mechanisms of resistance, compared to a situation 
where the same drug is always used and only one mode 
of resistance is required. 
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